YUGANDHAR PUVVALA - Dr Reddys Global Head of Supply Chain
| RDY Stock | USD 14.14 0.06 0.43% |
Executive
YUGANDHAR PUVVALA is Global Head of Supply Chain of Dr Reddys Laboratories since 2018.
| Age | 48 |
| Tenure | 6 years |
| Address | 8-2-337, Road No. 3, Hyderabad, India, 500034 |
| Phone | 91 40 4900 2900 |
| Web | https://www.drreddys.com |
Dr Reddys Management Efficiency
The company has Return on Asset of 0.104 % which means that on every $100 spent on assets, it made $0.104 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1927 %, implying that it generated $0.1927 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Dr Reddys' Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.15 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 16.9 B in 2024, whereas Total Assets are likely to drop slightly above 214.9 B in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Todd Pettingill | Ligand Pharmaceuticals Incorpor | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
| Garlan Adams | Crinetics Pharmaceuticals | N/A | |
| Srikanth MD | Connect Biopharma Holdings | N/A | |
| Simon Harford | Amicus Therapeutics | 64 | |
| Gregory Fuest | Passage Bio | N/A | |
| Keith Marschke | Ligand Pharmaceuticals Incorpor | N/A | |
| Ellen Rosenberg | Amicus Therapeutics | 61 | |
| Karl Whitney | Passage Bio | N/A | |
| Sue Browne | Passage Bio | N/A | |
| Matthew JD | Lyell Immunopharma | 48 | |
| Edna Maneval | Oric Pharmaceuticals | 64 | |
| Brendan Luu | Enanta Pharmaceuticals | 49 | |
| Eden Fucci | Passage Bio | N/A | |
| Robert MD | Crinetics Pharmaceuticals | N/A | |
| Patrik Esq | Amicus Therapeutics | N/A | |
| Matthew JD | Enanta Pharmaceuticals | 51 | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Jiang JD | Connect Biopharma Holdings | N/A | |
| Karen MD | Ligand Pharmaceuticals Incorpor | 74 | |
Management Performance
Dr Reddys Laboratories Leadership Team
Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDY. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MARC KIKUCHI, Chief Executive Officer, North America Generics | ||
| Krishna MS, Global Council | ||
| Venkata MBA, CEO Council | ||
| Leo Puri, Non-Executive Independent Director | ||
| Sandeep Poddar, Compliance Officer, Company Secretary | ||
| Satish Reddy, Co-Chairman of the Board | ||
| Patrick Aghanian, Chief Executive Officer, European Generics | ||
| Sumera Hasham, Senior officer | ||
| Arunabha RayChaudhuri, Head Director | ||
| Jayanth Sridhar, Global Council | ||
| Sanjay BTech, Global VP | ||
| Prasad Menon, Lead Non-Executive Independent Director | ||
| K Krishnan, Additional Independent Director | ||
| Shikha Sharma, Non-Executive Independent Director | ||
| Milan Kalawadia, CEO Council | ||
| Bharat Doshi, Non-Executive Independent Director | ||
| Gunupati BE, MD CoChairman | ||
| Raymond Vre, Global Head of Biologics | ||
| Bruce Carter, Non-Executive Independent Director | ||
| M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) | ||
| Parag Agarwal, Chief Financial Officer - Designate | ||
| MPharm MS, Senior President | ||
| Archana Bhaskar, Chief Human Resource Officer | ||
| Erez MBA, CEO Council | ||
| MS BTech, Chairman Council | ||
| Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients | ||
| Penny Wan, Additional Independent Director | ||
| G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director | ||
| P Yugandhar, Global Head of Supply Chain | ||
| Sushrut Kulkarni, Global Council | ||
| Sauri Gudlavalleti, Global Head of Integrated Product Development Organization | ||
| YUGANDHAR PUVVALA, Global Head of Supply Chain | ||
| K Singh, Chief Compliance Officer, Company Secretary | ||
| Allan Oberman, Non-Executive Independent Director | ||
| Anil Namboodiripad, Global Head of Proprietary Products | ||
| Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE | ||
| SANJAY SHARMA, Global Head of Manufacturing | ||
| Sridar Iyengar, Non-Executive Independent Director | ||
| Ganadhish Kamat, Executive Vice President and Global Head-Quality | ||
| Vivek Mittal, Interim Compliance Officer, General Counsel | ||
| Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI | ||
| Kalpana Morparia, Non-Executive Independent Director | ||
| Kumar Singh, Compliance Secretary | ||
| Richa Periwal, Head Analytics | ||
| Mannam Venkatanarasimham, Deputy Council | ||
| Deepak MBA, CEO Council | ||
| Bhethanabottla Phanimitra, Chief Council | ||
| MBA MBA, CEO Council | ||
| Mukesh Rathi, Chief Digital and Information Officer |
RDY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 11.69 B | ||||
| Shares Outstanding | 833.05 M | ||||
| Shares Owned By Institutions | 14.22 % | ||||
| Number Of Shares Shorted | 11.64 M | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.24 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.